Patents Assigned to GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
-
Patent number: 11234968Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.Type: GrantFiled: August 18, 2017Date of Patent: February 1, 2022Assignee: Guangzhou Virotech Pharmaceutical Co., Ltd.Inventors: Guangmei Yan, Haipeng Zhang, Yuan Lin, Suizhen Lin, Jing Cai, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
-
Patent number: 11235011Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: GrantFiled: November 12, 2019Date of Patent: February 1, 2022Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
-
Publication number: 20200085892Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: ApplicationFiled: November 12, 2019Publication date: March 19, 2020Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
-
Patent number: 10517909Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: GrantFiled: August 24, 2015Date of Patent: December 31, 2019Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTDInventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
-
Publication number: 20190183948Abstract: This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.Type: ApplicationFiled: August 18, 2017Publication date: June 20, 2019Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.Inventors: Guangmei YAN, Yaqian TAN, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Jing CAI, Wenbo ZHU, Wei YIN
-
Publication number: 20190167737Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.Type: ApplicationFiled: August 18, 2017Publication date: June 6, 2019Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.Inventors: Guangmei YAN, Jing CAI, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
-
Publication number: 20190167641Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.Type: ApplicationFiled: August 18, 2017Publication date: June 6, 2019Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.Inventors: Guangmei YAN, Haipeng ZHANG, Yuan LIN, Suizhen LIN, Jing CAI, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
-
Publication number: 20170304380Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: ApplicationFiled: August 24, 2015Publication date: October 26, 2017Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.Inventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN